Planet Briefing

First published · Last updated

Co-administration of empagliflozin and curcumin attenuates the development of MASLD by modulating lipid metabolism and adipose tissue browning in HFD-fed C57BL/6J mice

A journal article (Elsevier BV) published 2026-09-01 reports that co-administration of empagliflozin and curcumin attenuates development of MASLD in HFD-fed C57BL/6J mice. The supplied excerpt contains only publisher and content-type metadata and provides no further study details.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence
4/10
Geographic reach
1/10
Global importance
2/10
Impact magnitude
2/10
Positivity
6/10
Urgency
1/10

Why it matters

The article reports a potentially beneficial preclinical effect on MASLD in an animal model.

Sources

Report an issue